Articles with public access mandates - Edwin Roger Parra CuentasLearn more
Not available anywhere: 8
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
M Provencio, E Nadal, A Insa, MR García-Campelo, J Casal-Rubio, ...
The Lancet Oncology 21 (11), 1413-1422, 2020
Mandates: European Commission, Government of Spain
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial
RR Patel, K He, HB Barsoumian, JY Chang, C Tang, V Verma, ...
Radiotherapy and Oncology 162, 60-67, 2021
Mandates: US National Institutes of Health
Programmed death cell ligand 1 (pd-l1) is associated with survival in stage I non–small cell lung cancer
B Sepesi, EP Cuentas, JR Canales, C Behrens, AM Correa, A Vaporciyan, ...
Seminars in thoracic and cardiovascular surgery 29 (3), 408-415, 2017
Mandates: US Department of Defense, US National Institutes of Health
Female gender predicts augmented immune infiltration in lung adenocarcinoma
C Behrens, P Rocha, ER Parra, L Feng, J Rodriguez-Canales, LM Solis, ...
Clinical Lung Cancer 22 (3), e415-e424, 2021
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Imaging-genetic data mapping for clinical outcome prediction via supervised conditional gaussian graphical model
X Zhu, J Yao, G Xiao, Y Xie, J Rodriguez-Canales, ER Parra, C Behrens, ...
2016 IEEE international conference on bioinformatics and biomedicine (BIBM …, 2016
Mandates: US National Science Foundation
Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non …
J Machado-Rugolo, AT Fabro, D Ascheri, C Farhat, AM Ab'Saber, ...
Human pathology 83, 177-191, 2019
Mandates: US National Institutes of Health
CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti‐CD30 CAR T‐cell therapy
ML Marques‐Piubelli, DH Kim, LJ Medeiros, W Lu, K Khan, ...
Histopathology 83 (1), 143-148, 2023
Mandates: US National Institutes of Health
Pathological pulmonary vascular remodeling is induced by type V collagen in a model of scleroderma
RG Marangoni, BD Korman, ER Parra, APP Velosa, HV Barbeiro, ...
Pathology-Research and Practice 220, 153382, 2021
Mandates: US National Institutes of Health
Available somewhere: 97
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ...
Cancer discovery 8 (7), 822-835, 2018
Mandates: US National Institutes of Health, V Foundation, USA
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic …
F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ...
Cancer discovery 5 (8), 860-877, 2015
Mandates: US National Institutes of Health, V Foundation, USA
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Y Wang, DH Wiesnoski, BA Helmink, V Gopalakrishnan, K Choi, ...
Nature medicine 24 (12), 1804-1808, 2018
Mandates: US National Institutes of Health
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ...
Nature medicine 27 (3), 504-514, 2021
Mandates: US National Institutes of Health
A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition
MP Mak, P Tong, L Diao, RJ Cardnell, DL Gibbons, WN William, ...
Clinical Cancer Research 22 (3), 609-620, 2016
Mandates: US National Institutes of Health, LUNGevity Foundation, USA, V Foundation, USA
Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues
ER Parra, N Uraoka, M Jiang, P Cook, D Gibbons, MA Forget, ...
Scientific reports 7 (1), 13380, 2017
Mandates: US National Institutes of Health
A proteogenomic portrait of lung squamous cell carcinoma
S Satpathy, K Krug, PMJ Beltran, SR Savage, F Petralia, C Kumar-Sinha, ...
Cell 184 (16), 4348-4371. e40, 2021
Mandates: US National Institutes of Health
Association of interferon‐and transforming growth factor β–regulated genes and macrophage activation with systemic sclerosis–related progressive lung fibrosis
RB Christmann, P Sampaio‐Barros, G Stifano, CL Borges, ...
Arthritis & rheumatology 66 (3), 714-725, 2014
Mandates: US National Institutes of Health
The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
JM Taube, G Akturk, M Angelo, EL Engle, S Gnjatic, S Greenbaum, ...
Journal for immunotherapy of cancer 8 (1), 2020
Mandates: US National Institutes of Health
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
H Kadara, M Choi, J Zhang, ER Parra, J Rodriguez-Canales, SG Gaffney, ...
Annals of Oncology 28 (1), 75-82, 2017
Mandates: US Department of Defense, US National Institutes of Health
Comprehensive T cell repertoire characterization of non-small cell lung cancer
A Reuben, J Zhang, SH Chiou, RM Gittelman, J Li, WC Lee, J Fujimoto, ...
Nature communications 11 (1), 603, 2020
Mandates: US Department of Defense, US National Institutes of Health, Howard Hughes …
TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence
A Reuben, R Gittelman, J Gao, J Zhang, EC Yusko, CJ Wu, R Emerson, ...
Cancer discovery 7 (10), 1088-1097, 2017
Mandates: US Department of Defense, US National Institutes of Health
Publication and funding information is determined automatically by a computer program